Evaluating Cardiovascular Risk Factors in the Hemophilia Population

Cardiovascular Disease and Cardiovascular Risk Factors in Older men with Moderate and Severe Hemophilia

ASH 2015 (Orlando, December 5-8) Previously, men with hemophilia were thought to be protected from cardiovascular disease (CVD). In recent times, it has been shown that cardiovascular events do occur in men with hemophilia and some studies presented earlier this year showed potentially increased risk. According to data presented at the American Society of Hematology (ASH) 2015 Annual Meeting, the American Thrombosis and Hemostasis Network’s ATHN-1 study was done to show the prevalence (number or percentage of people who have a disease within a given time frame) of cardiovascular disease and risk factors for CVD in older men with moderate and severe hemophilia. The prevalence rate of CVD (defined as chest pain, heart attack, stroke, and mini stroke) was 9.7%, significantly lower than the 23% prevalence of CVD in similar aged men without hemophilia in the long term Atherosclerosis Risk in Communities (ARIC) cohort. None of the men with CVD were on antiplatelet or anticoagulant medications which are commonly used treatments for CVD.

These findings from ATHN-1 suggest that men with hemophilia may be protected from developing abnormal blood clots. Smoking significantly increased the occurrence of CVD among men with hemophilia. Additional information is needed to determine if the approach to prophylaxis with factor concentrates or other therapies should be altered in this population.

 

The ATHN-1 study was supported by a grant to ATHN from the Centers for Disease Control and Prevention (CDC).